Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viatris Inc (VTRS) vs Williams Companies Inc (WMB) Price & Performance

Viatris IncTrade
Williams Companies IncTrade

Price performance (Past 24H)

Key statistics

Viatris Inc vs Williams Companies Inc — how do they compare? Viatris Inc trades at $16.28 (market cap $18.69B), while Williams Companies Inc trades at $73.37 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 4.7× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.

VTRSWMB
Market Cap
$18.69B$88.45B
Sector
HealthEnergy
52-Week High
$17.86$79.40
52-Week Low
$9.49$56.51
Enterprise Value
$30.80B$119.07B
Dividend Yield
2.95%2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Viatris Inc

Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.

Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.

Williams Companies Inc

WMB trades at $73.72, up 2.6% today, with a bullish technical signal and strong analyst support. The company reported mixed quarterly earnings but raised full-year EBITDA guidance to $8.4 billion following its $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast footprint. Fundamentals show robust profitability with a 25.18% net income margin and 24.02% ROE, though valuation multiples like a P/E of 28.81 appear elevated.

The outlook is positive, driven by growth initiatives and stable cash flows, but risks include execution of the large acquisition and sensitivity to energy demand. With a consensus price target of $87.14 implying 18% upside, the stock offers growth potential tempered by integration challenges and debt levels.

Returns comparison

Trailing returns across standard periods

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS

About Williams Companies Inc

Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.

Read more on WMB